Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial
Rui-Hua Xu, Yanqiao Zhang, Hongming Pan, Jifeng Feng, Tao Zhang, Tianshu Liu, Yanru Qin, Shukui Qin, Xianli Yin, Baorui Liu, Yi Ba, Nong Yang, Pei Jye Voon, Suebpong Tanasanvimon, Chan Zhou, Wan Li Zhang, Lin Shen
Topics & Concepts
RamucirumabMedicineInternal medicineGastroesophageal JunctionPaclitaxelOncologyClinical trialAdenocarcinomaPhases of clinical researchGastroenterologyGastric adenocarcinomaCancerChemotherapyApatinibSurgeryRandomized controlled trialPhase (matter)Gastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentPancreatic and Hepatic Oncology Research